|
1
|
Cleton-Jansen AM, Anninga JK, Briaire-de
Bruijn IH, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AH
and Hogendoorn PC: Profiling of high-grade central osteosarcoma and
its putative progenitor cells identifies tumourigenic pathways. Br
J Cancer. 101:1909–1918. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng W, Wan R, Zheng Y, Singh SR and Wei
Y: Hypoxia, stem cells and bone tumor. Cancer Lett. 313:129–136.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao N, Sun BC, Sun T, Ma YM, Zhao XL, Liu
ZY, Dong XY, Che N, Mo J and Gu Q: Hypoxia-induced vasculogenic
mimicry formation via VE-cadherin regulation by Bcl-2. Med Oncol.
29:3599–3607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pàez-Ribes M, Allen E, Hudock J, Takeda T,
Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D and Casanovas O:
Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer Cell.
15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason
GA, Christensen JG and Kerbel RS: Accelerated metastasis after
short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loges S, Mazzone M, Hohensinner P and
Carmeliet P: Silencing or fueling metastasis with VEGF inhibitors:
Antiangiogenesis revisited. Cancer Cell. 15:167–170. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nurwidya F, Takahashi F, Minakata K,
Murakami A and Takahashi K: From tumor hypoxia to cancer
progression: The implications of hypoxia-inducible factor-1
expression in cancers. Anat Cell Biol. 45:73–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dai ZJ, Gao J, Ma XB, Yan K, Liu XX, Kang
HF, Ji ZZ, Guan HT and Wang XJ: Up-regulation of hypoxia inducible
factor-1α by cobalt chloride correlates with proliferation and
apoptosis in PC-2 cells. J Exp Clin Cancer Res. 31:282012.
View Article : Google Scholar
|
|
9
|
Knowles HJ, Schaefer KL, Dirksen U and
Athanasou NA: Hypoxia and hypoglycaemia in Ewing’s sarcoma and
osteosarcoma: Regulation and phenotypic effects of
hypoxia-inducible factor. BMC Cancer. 10:3722010. View Article : Google Scholar
|
|
10
|
El Naggar A, Clarkson P, Zhang F, Mathers
J, Tognon C and Sorensen PH: Expression and stability of hypoxia
inducible factor 1α in osteosarcoma. Pediatr Blood Cancer.
59:1215–1222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li
Y, Banerjee S, Padhye S and Sarkar FH: Hypoxia induced
aggressiveness of prostate cancer cells is linked with deregulated
expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.
PLoS One. 7:e437262012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dai X, Ma W, He XJ and Jha RK: Elevated
expression of adrenomedullin is correlated with prognosis and
disease severity in osteosarcoma. Med Oncol. 30:3472013. View Article : Google Scholar
|
|
13
|
Hay DL, Walker CS and Poyner DR:
Adrenomedullin and calcitonin gene-related peptide receptors in
endocrine-related cancers: Opportunities and challenges. Endocr
Relat Cancer. 18:C1–C14. 2011. View Article : Google Scholar
|
|
14
|
Kitamura K, Kangawa K, Kawamoto M, Ichiki
Y, Nakamura S, Matsuo H and Eto T: Adrenomedullin: A novel
hypotensive peptide isolated from human pheochromocytoma. Biochem
Biophys Res Commun. 192:553–560. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nikitenko LL, Fox SB, Kehoe S, Rees MC and
Bicknell R: Adrenomedullin and tumour angiogenesis. Br J Cancer.
94:1–7. 2006. View Article : Google Scholar
|
|
16
|
Dai X, Ma W, Jha RK and He X:
Adrenomedullin and its expression in cancers and bone. A literature
review. Front Biosci (Elite Ed). 2:1073–1080. 2010. View Article : Google Scholar
|
|
17
|
Kaseta MK, Khaldi L, Gomatos IP,
Tzagarakis GP, Alevizos L, Leandros E, Papagelopoulos PJ and
Soucacos PN: Prognostic value of bax, bcl-2, and p53 staining in
primary osteosarcoma. J Surg Oncol. 97:259–266. 2008. View Article : Google Scholar
|
|
18
|
Cory S, Huang DC and Adams JM: The Bcl-2
family: Roles in cell survival and oncogenesis. Oncogene.
22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferrari S, Bertoni F, Zanella L, Setola E,
Bacchini SP, Alberghini M, Versari M and Bacci G: Evaluation of
P-glyco-protein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and
metachronous lung metastases in patients with high-grade
osteosarcoma. Cancer. 100:1936–1942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Takeuchi S, Ohara N and Maruo T:
Paradoxically abundant expression of Bcl-2 and adrenomedullin in
invasive cervical squamous carcinoma. Int J Clin Oncol. 8:83–89.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oehler MK, Norbury C, Hague S, Rees MC and
Bicknell R: Adrenomedullin inhibits hypoxic cell death by
upregulation of Bcl-2 in endometrial cancer cells: A possible
promotion mechanism for tumour growth. Oncogene. 20:2937–2945.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park SC, Yoon JH, Lee JH, Yu SJ, Myung SJ,
Kim W, Gwak GY, Lee SH, Lee SM, Jang JJ, et al: Hypoxia-inducible
adrenomedullin accelerates hepatocellular carcinoma cell growth.
Cancer Lett. 271:314–322. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abasolo I, Montuenga LM and Calvo A:
Adrenomedullin prevents apoptosis in prostate cancer cells. Regul
Pept. 133:115–122. 2006. View Article : Google Scholar
|
|
24
|
Chen X, Yang TT, Wang W, Sun HH, Ma BA, Li
CX, Ma Q, Yu Z and Fan QY: Establishment and characterization of
human osteosarcoma cell lines with different pulmonary metastatic
potentials. Cytotechnology. 61:37–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ramachandran V, Arumugam T, Hwang RF,
Greenson JK, Simeone DM and Logsdon CD: Adrenomedullin is expressed
in pancreatic cancer and stimulates cell proliferation and invasion
in an autocrine manner via the adrenomedullin receptor, ADMR.
Cancer Res. 67:2666–2675. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martínez A, Vos M, Guédez L, Kaur G, Chen
Z, Garayoa M, Pío R, Moody T, Stetler-Stevenson WG, Kleinman HK, et
al: The effects of adrenomedullin overexpression in breast tumor
cells. J Natl Cancer Inst. 94:1226–1237. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen P, Pang X, Zhang Y and He Y: Effect
of inhibition of the adrenomedullin gene on the growth and
chemosensitivity of ovarian cancer cells. Oncol Rep. 27:1461–1466.
2012.PubMed/NCBI
|
|
28
|
Shimizu S, Eguchi Y, Kosaka H, Kamiike W,
Matsuda H and Tsujimoto Y: Prevention of hypoxia-induced cell death
by Bcl-2 and Bcl-xL. Nature. 374:811–813. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu X, Cai ZD, Lou LM and Zhu YB:
Expressions of p53, c-MYC, BCL-2 and apoptotic index in human
osteosarcoma and their correlations with prognosis of patients.
Cancer Epidemiol. 36:212–216. 2012. View Article : Google Scholar
|
|
30
|
Zhao Y, Zhang CL, Zeng BF, Wu XS, Gao TT
and Oda Y: Enhanced chemosensitivity of drug-resistant osteosarcoma
cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res
Commun. 390:642–647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ramos JW: The regulation of extracellular
signal-regulated kinase (ERK) in mammalian cells. Int J Biochem
Cell Biol. 40:2707–2719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Atabakhsh E and Schild-Poulter C: RanBPM
is an inhibitor of ERK signaling. PLoS One. 7:e478032012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Deville JL, Salas S, Figarella-Branger D,
Ouafik L and Daniel L: Adrenomedullin as a therapeutic target in
angiogenesis. Expert Opin Ther Targets. 14:1059–1072. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Uzan B, Villemin A, Garel JM and Cressent
M: Adrenomedullin is anti-apoptotic in osteoblasts through CGRP1
receptors and MEK-ERK pathway. J Cell Physiol. 215:122–128. 2008.
View Article : Google Scholar
|
|
35
|
Vacotto M, Coso O and Fiszer de Plazas S:
Programmed cell death and differential JNK, p38 and ERK response in
a prenatal acute hypoxic hypoxia model. Neurochem Int. 52:857–863.
2008. View Article : Google Scholar
|
|
36
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zambon AC, Wilderman A, Ho A and Insel PA:
Increased expression of the pro-apoptotic protein BIM, a mechanism
for cAMP/protein kinase A (PKA)-induced apoptosis of immature T
cells. J Biol Chem. 286:33260–33267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nagaya N, Mori H, Murakami S, Kangawa K
and Kitamura S: Adrenomedullin: Angiogenesis and gene therapy. Am J
Physiol Regul Integr Comp Physiol. 288:R1432–R1437. 2005.
View Article : Google Scholar : PubMed/NCBI
|
